-Reuters
Jefferies Downgrades Vertex Pharmaceuticals to Hold, Announces $340 Price Target
Jefferies analyst Michael Yee downgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Buy to Hold and announces $340 price target.
Related Posts
Co-Diagnostics, Inc. Initiates Clinical Evaluations For Its At-Home And Point-Of-Care Co-Dx PCR Home Platform
Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced
WPP & Spotify Announce First-Of-Its-Kind Global Partnership; Spotify Will Be The First Audio Platform To Be Integrated Directly Into WPP’s Products And Solutions
Spotify will be the first audio platform to be integrated directly into WPP's products and solutions.
WPP (NYSE:WPP) and Spotify today announced a new global strategic partnership that will enable WPP to offer its
Williams-Sonoma, ESS Tech And Other Big Stocks Moving Higher On Monday
U.S. stocks traded lower, with the Dow Jones falling around 100 points on Monday. Here are some big stocks recording gains in today’s session.